MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus. This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.

Denka Corp., part of Denka Co., Ltd., is an American company located in New York, NY. The firm manufactures and distributes chemical products.

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

Changchun BCHT Biotechnology Co. engages in the research and development, production and sale of human vaccines. It specializes in prevention and treatment of infectious diseases. Its products include chickenpox vaccine, rabies vaccine, and freeze-dried nasal spray flu vaccine. The company was founded on March 4, 2004 and is headquartered in Changchun, China.

Jemincare is a pharmaceutical company that engages in medical care, clean energy, mineral development, and industrial investment. The company was founded in 1999 and is headquartered in Shanghai, China.

Shanghai Jiyu Pharmaceutical Technology Co., Ltd., established on 2018-06-22, The scope of business includes engaging in medical technology,Technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,drug development,Medical device management,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Kashiv Biosciences LLC is a private company headquartered in Piscataway, NJ, with subsidiaries in India, that operates as a biopharmaceutical company which offers drug delivery technologies, biosimilars and specialty pharmaceutical products.\nThe company says this about itself: Kashiv Biosciences, LLC is a premier, fully integrated biopharmaceutical company developing advanced-stage biosimilars and specialty biopharmaceutical products. The company is headquartered in Piscataway, NJ with facilities in Chicago, IL and India that all together provide formulation development, analytical testing, biosimilar characterization, and manufacturing of small and large molecules.

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

Bio-Thera Solutions Ltd. engages in the research, development, and production of innovative drugs and biosimilar drugs for the treatment of tumours, autoimmune diseases, cardiovascular diseases, other threats to human life, and major health diseases. The company was founded by Sheng Feng Li on July 28, 2003 and is headquartered in Guangzhou, China.

Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd., established on 2014-06-23, Business scope includes biomedical research,to develop,Research and development of pharmaceutical intermediates,Sales(In addition to drugs,Biological product),And provide related technology development,technical consulting,Technical Services,technology transfer,Import and export business of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Chongqing Genrix Biopharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of antibody drugs. Its key antibody drugs are mainly for autoimmune diseases, infectious diseases, and tumors. The company was founded on October 20, 2015 and is headquartered in Chongqing, China.

Beijing Zhiren Meibo Biotechnology Co., Ltd., established on 2015-05-21, Business scope includes biotechnology development,technology transfer,Technical Services,technical consulting.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Jiangsu Academy of Agricultural Sciences is a Chinese private company located in Nanjing, with subsidiaries in China, that engages in agriculture research and development.